Results indicated that miR-132-5p attenuated altered expression due to ketamine administration, restoring levels of BDNF, MeCP2 and TGF-b1 in the PFC, and improving depression like behaviours (Ma et al. 2022). Here, MECP2 is linked to depressive symptom measurement.